Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $30.20.

Several research firms recently issued reports on GLUE. Weiss Ratings reiterated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Cowen reaffirmed a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Wednesday. Wells Fargo & Company boosted their price target on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday. Jefferies Financial Group reissued a “buy” rating and issued a $31.00 price objective on shares of Monte Rosa Therapeutics in a research note on Wednesday. Finally, Wedbush restated an “outperform” rating and issued a $37.00 price objective on shares of Monte Rosa Therapeutics in a report on Wednesday.

Insider Activity at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total value of $128,396.34. Following the completion of the transaction, the chief executive officer owned 618,937 shares in the company, valued at $14,538,830.13. The trade was a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 6.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC purchased a new stake in Monte Rosa Therapeutics during the 4th quarter worth about $30,000. Russell Investments Group Ltd. purchased a new stake in shares of Monte Rosa Therapeutics during the third quarter worth approximately $32,000. Brighton Jones LLC purchased a new stake in shares of Monte Rosa Therapeutics during the second quarter worth approximately $48,000. Lazard Asset Management LLC raised its holdings in Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after acquiring an additional 3,262 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in Monte Rosa Therapeutics in the second quarter worth approximately $54,000. 79.96% of the stock is currently owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE stock opened at $24.28 on Friday. The firm has a market cap of $1.58 billion, a P/E ratio of 75.88 and a beta of 1.60. The firm’s 50 day moving average price is $16.01 and its 200-day moving average price is $9.78. Monte Rosa Therapeutics has a one year low of $3.50 and a one year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.06. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%.The company had revenue of $12.77 million for the quarter, compared to analyst estimates of $7.37 million. As a group, research analysts predict that Monte Rosa Therapeutics will post -1.49 EPS for the current fiscal year.

Key Monte Rosa Therapeutics News

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Interim Phase I data showed MRT‑8102 produces deep NEK7 degradation and drove a large reduction in inflammation markers, which triggered a big intraday rally in the stock. GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
• Positive Sentiment: Early trial readouts reported ~85% CRP reduction (a key inflammation marker), reinforcing clinical promise for MRT‑8102 and sparking investor enthusiasm. Monte Rosa stock surges after positive data shows 85% CRP reduction
• Positive Sentiment: Analysts reacted to the clinical news with bullish moves — Guggenheim raised its PT to $34 and issued a Buy, and Wells Fargo raised its PT to $30 with an Overweight. These actions support upside from fundamentals if clinical progress continues. Benzinga
• Positive Sentiment: Zacks upgraded GLUE from Hold to Strong Buy amid the data-driven momentum, adding to short‑term buyer interest. Zacks.com upgrade
• Neutral Sentiment: Several market watchers flagged GLUE as a “stock on the move,” highlighting momentum and technical strength that could attract momentum traders. Monte Rosa Therapeutics (GLUE) is on the Move
• Negative Sentiment: Monte Rosa priced an underwritten public offering to raise roughly $300 million: 11,125,000 shares at $24.00 plus 1,375,000 pre‑funded warrants at $23.9999. The timing — immediately after a sharp rally — increases share supply and dilution risk, which likely weighed on the stock. Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.